AN2 Therapeutics EBIT

AN2 Therapeutics (ANTX) currently reports a EBIT of $-37M as of March 2026. That compares with $-50M in the prior-year period — up 26.9% year over year. That is above the sector sector average of $-63M. Use the charts on this page to explore AN2 Therapeutics's EBIT history and peer comparisons.

AN2 Therapeutics's EBIT increased from $-50M to $-37M — a 26.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AN2 Therapeutics's EBIT of $-37M is higher than the its sector sector average of $-63M. That is roughly 41.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AN2 Therapeutics reported $-37M in EBIT as of March 2026. That compares with $-50M in the prior-year period — up 26.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-37M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for AN2 Therapeutics, and consider following ANTX for alerts when major investors trade the stock.